Currently, the only cure for alpha thalassemia is a bone marrow transplant, but the success of gene therapies for related conditions points to a potential new cure.
A biopharmaceutical company established a new method for isolating and editing hematopoietic stem cells from patients to provide stem cell therapies for diseases such as sickle cell disease.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?